NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: PeptiSlim

Published 12 Nov 2026. 43-page investigative report on who is behind PeptiSlim: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 75 Finnrick lab tests, PeptiSlim's overall pass rate is 84% (63 pass / 12 fail). The record is product-specific, not vendor-wide reassurance. Tirzepatide and Retatrutide carry the strongest GLP-1 signal, while Tesamorelin is fail-heavy and Cagrilintide is thin and weak. Tirzepatide still needs current batch verification because the trail includes a historical identity failure.

The business identity is harder than the storefront suggests. The U.S. PeptiSlim shop discloses no legal entity or physical address; its contact set uses Gmail, Hong Kong phone numbers and GMT+8 support hours, while shipping language points to cross-border fulfillment. The operating geography reads China/Hong Kong, but the natural-person owner remains unresolved.

The certificate story splits sharply. The U.S. gallery contains real Janoshik evidence, including a verified PeptiSlim-commissioned Retatrutide task, but it also mixes vendor-commissioned and LMR supplier-commissioned reports without a clean vial-to-lot workflow. The Australian side is more serious: the AU/BioSynteq library fits a fixed purity-to-quantity template across every reviewed single-peptide certificate, and file/origin fingerprints tie the claimed lab surface back to the AU storefront.

PeptiSlim also sits in a wider channel cluster. Lilipetide shares infrastructure and adjacent testing-window signals; Bad Witch Labs and Theocdn republish or reuse PeptiSlim Janoshik certificates; PeptiSlimBio carries an unresolved 2018 San Diego/ISO/GMP history claim on a 2026 domain. The buyer takeaway is directional: prefer verifiable Janoshik-backed lots on PeptiSlim's stronger GLP-1 products, and do not treat AU/BioSynteq screenshots or social-reseller pages as batch assurance.

Inside the full report:

  • Per-product pass/fail rates and methodology-divergence charts for all 6 products
  • Janoshik task/key verification and U.S. COA provenance analysis
  • AU/BioSynteq template mapping plus header/MD5 origin comparison
  • RDAP, Shoplazza and storefront map across PeptiSlim, AU, Lilipetide and PeptiSlimBio
  • Bad Witch Labs, Noxera and Theocdn COA-reuse analysis
  • AU merchant-opacity review: ABR search, payment descriptor and terms

Risk assessment

  • AU certificate-integrity risk — high: AU PeptiSlim/BioSynteq COAs fit a fixed template across 66 of 66 single-peptide certificates and share origin/file fingerprints with the AU storefront.
  • Batch-traceability and COA-to-vial risk — high: US gallery mixes PeptiSlim-commissioned and LMR supplier-commissioned Janoshik reports with blank or Unknown batch fields; PeptiSlim COAs are reused by other vendors.
  • AU merchant-identity and payment risk — high: AU storefront has no PeptiSlim ABN found, hides the bank-statement descriptor, gives conflicting payment-method language and uses final-sale terms.
  • Brand-confusion and unofficial-channel risk — high: PeptiSlim-branded and adjacent surfaces include elitepeptide66.com, au.peptislim.com, peptislimbio.com, Lean Life, PeptiSlim PH and Lilipetide with no official-channel or authorized-reseller list.
  • Sister-network transaction risk — medium: Lilipetide shares infrastructure and testing-window signals with PeptiSlim and has Trustpilot complaints about post-payment insurance/testing-fee demands; not proven for PeptiSlim.
  • Tesamorelin quality risk — high: PeptiSlim Tesamorelin is fail-heavy in Finnrick testing at 44.52% across 4 tests, with 1 pass and 3 failures.
  • Cagrilintide quality risk — medium: PeptiSlim Cagrilintide is thin and weak in Finnrick testing at 53.84% across 2 tests, with 1 pass and 1 failure.
  • Semaglutide quality risk — medium: PeptiSlim Semaglutide is a middling choice at 68.63% across 4 Finnrick tests, not a catalog strength.